US EditionPublished • loading... • Updated
Eli Lilly’s Retatrutide Shows Efficacy for Diabetes, Weight Management
Retatrutide led to 16.8% weight loss and a 1.9% HbA1c drop in Type 2 diabetes patients after 40 weeks, outperforming Eli Lilly’s current bestselling drug, tirzepatide.
- On Thursday, Eli Lilly announced its experimental drug retatrutide successfully completed a Phase 3 trial, helping Type 2 diabetes patients manage blood sugar levels and lose weight.
- Dubbed a "triple G" drug, retatrutide mimics three hunger-regulating hormones, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, over 40 weeks.
- Around 26.5% of patients experienced nausea as a gastrointestinal side effect, while discontinuation rates reached up to 5% due to these reactions.
- Ken Custer, president of Lilly Cardiometabolic Health, said the company is "very excited" by the results, while University of Toronto professor Daniel Drucker called the trial data "very solid."
- Novo Nordisk is racing to catch up to Lilly as retatrutide nears potential market entry, while Lilly currently leads the sector with its blockbuster injection Zepbound.
Insights by Ground AI
18 Articles
18 Articles
Lilly’s experimental diabetes shot yields record weight loss in study
One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any drug currently on the market, underscoring its potential in the increasingly crowded race for next-generation therapies.
·New Hampshire, United States
Read Full Article
The pharmacokinetic giant shared Phase 3 study results evaluating the effectiveness of retatrutide, a triple agonist acting in three metabolic receptors, unlike previous generations.
·Brazil
Read Full Article
Coverage Details
Total News Sources18
Leaning Left2Leaning Right2Center8Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
